Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line

Jacob J. Henderson, Jacob P. Wagner, Nicolle E. Hofmann, Christopher A. Eide, Yoon-Jae Cho, Brian Druker, Monika Davare

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Medulloblastoma is the most common malignant brain tumor of childhood. To identify targetable vulnerabilities, we employed inhibitor screening that revealed mTOR inhibitor hypersensitivity in the MYC-overexpressing medulloblastoma cell line, D341. Concomitant exome sequencing unveiled an uncharacterized missense mutation, TSC2A415V, in these cells. We biochemically demonstrate that the TSC2A415V mutation is functionally deleterious, leading to shortened half-life and proteasome-mediated protein degradation. These data suggest that MYC cooperates with activated kinase pathways, enabling pharmacologic intervention in these treatment refractory tumors. We propose that identification of activated kinase pathways may allow for tailoring targeted therapy to improve survival and treatment-related morbidity in medulloblastoma.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - 2017

Fingerprint

Medulloblastoma
Tuberous Sclerosis
Cell Line
Mutation
Phosphotransferases
Exome
Missense Mutation
Proteasome Endopeptidase Complex
Brain Neoplasms
Proteolysis
Half-Life
Hypersensitivity
Morbidity
Neoplasms
Therapeutics

Keywords

  • Everolimus
  • Medulloblastoma
  • Targeted therapy
  • Tuberous sclerosis complex

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{fca0c5ad378e420b8affce810b440793,
title = "Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line",
abstract = "Medulloblastoma is the most common malignant brain tumor of childhood. To identify targetable vulnerabilities, we employed inhibitor screening that revealed mTOR inhibitor hypersensitivity in the MYC-overexpressing medulloblastoma cell line, D341. Concomitant exome sequencing unveiled an uncharacterized missense mutation, TSC2A415V, in these cells. We biochemically demonstrate that the TSC2A415V mutation is functionally deleterious, leading to shortened half-life and proteasome-mediated protein degradation. These data suggest that MYC cooperates with activated kinase pathways, enabling pharmacologic intervention in these treatment refractory tumors. We propose that identification of activated kinase pathways may allow for tailoring targeted therapy to improve survival and treatment-related morbidity in medulloblastoma.",
keywords = "Everolimus, Medulloblastoma, Targeted therapy, Tuberous sclerosis complex",
author = "Henderson, {Jacob J.} and Wagner, {Jacob P.} and Hofmann, {Nicolle E.} and Eide, {Christopher A.} and Yoon-Jae Cho and Brian Druker and Monika Davare",
year = "2017",
doi = "10.1002/pbc.26553",
language = "English (US)",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line

AU - Henderson, Jacob J.

AU - Wagner, Jacob P.

AU - Hofmann, Nicolle E.

AU - Eide, Christopher A.

AU - Cho, Yoon-Jae

AU - Druker, Brian

AU - Davare, Monika

PY - 2017

Y1 - 2017

N2 - Medulloblastoma is the most common malignant brain tumor of childhood. To identify targetable vulnerabilities, we employed inhibitor screening that revealed mTOR inhibitor hypersensitivity in the MYC-overexpressing medulloblastoma cell line, D341. Concomitant exome sequencing unveiled an uncharacterized missense mutation, TSC2A415V, in these cells. We biochemically demonstrate that the TSC2A415V mutation is functionally deleterious, leading to shortened half-life and proteasome-mediated protein degradation. These data suggest that MYC cooperates with activated kinase pathways, enabling pharmacologic intervention in these treatment refractory tumors. We propose that identification of activated kinase pathways may allow for tailoring targeted therapy to improve survival and treatment-related morbidity in medulloblastoma.

AB - Medulloblastoma is the most common malignant brain tumor of childhood. To identify targetable vulnerabilities, we employed inhibitor screening that revealed mTOR inhibitor hypersensitivity in the MYC-overexpressing medulloblastoma cell line, D341. Concomitant exome sequencing unveiled an uncharacterized missense mutation, TSC2A415V, in these cells. We biochemically demonstrate that the TSC2A415V mutation is functionally deleterious, leading to shortened half-life and proteasome-mediated protein degradation. These data suggest that MYC cooperates with activated kinase pathways, enabling pharmacologic intervention in these treatment refractory tumors. We propose that identification of activated kinase pathways may allow for tailoring targeted therapy to improve survival and treatment-related morbidity in medulloblastoma.

KW - Everolimus

KW - Medulloblastoma

KW - Targeted therapy

KW - Tuberous sclerosis complex

UR - http://www.scopus.com/inward/record.url?scp=85017499325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017499325&partnerID=8YFLogxK

U2 - 10.1002/pbc.26553

DO - 10.1002/pbc.26553

M3 - Article

C2 - 28409891

AN - SCOPUS:85017499325

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -